Skip Navigation

Visiting Dana-Farber? See our prescreening and mask requirements.

Haesook T. Kim, PhD


No Ratings Available - Why Not?

No Photo


  • Principal Research Scientist, Dana-Farber Cancer Institute/ Harvard School of Public Health

Contact Information

  • Office Phone Number(617) 632-6856
  • Fax(617) 632-2444


Dr. Kim received her PhD in 1994 from the University of North Carolina at Chapel Hill. After graduation, she worked for the National Institute of Child Health and Human Development and later became an Assistant professor at the University of Pittsburgh. She joined DFCI in 1999, where she has served as a biostatistician for leukemia, stem cell transplantation, cancer vaccine studies, and studies of human cell therapies.  Dr. Kim is currently a principal research scientist.


Competing risks data analysis, time-to-event data analysis, design of clinical trials with special emphasis on hematopoietic stem cell transplantation and cancer vaccine studies, missing data analysis, and high throughput data analysis.

Dr. Kim’s research involves the design, conduct, analysis and reporting of translational clinical trials, database and laboratory studies pertaining to hematopoietic stem cell transplantation (HSCT) and cancer vaccine projects at Dana-Farber/Harvard Cancer Center (DF/HCC), as well as leukemia-related translational clinical and laboratory studies conducted outside of DF/HCC. 

Her statistical research focuses on statistical issues of competing risks data, time-to-event data, designing clinical trials with special emphasis on stem cell transplantation and cancer vaccine studies, missing data analysis, and high throughput data analysis.

The effectiveness of a cancer treatment is typically measured by the disease-free survival probability and its compliment is the treatment failure probability which can be further partitioned by probabilities of disease recurrence and death due to the treatment related complications (termed ‘treatment related mortality’). The probability of disease recurrence gives information on how well the treatment cures the initial disease whereas the probability of treatment related mortality gives an indication of how toxic the treatment itself is. In many cases, there is a trade-off between the two competing risks: disease recurrence and treatment related mortality. These probabilities together help us understand the efficacy of a cancer treatment.

Allogeneic hematopoietic stem cell transplantation (HSCT) can deliver a cure for a variety of malignant and non-malignant hematologic disorders. Cure through HSCT may be achieved through the cytotoxicity of the conditioning regimen or through the graft-versus-tumor (GVT) effect brought about through adoptive immunotherapy.  However, both of those effects are also intimately tied to the toxicity of HSCT; an increase in conditioning intensity may be associated with a decreased risk of disease recurrence and graft failure, but also with an increased risk of mortality; and the strength of the GVT effect is closely tied to the risk and severity of graft-versus-host disease (GVHD) and its considerable attendant morbidity and mortality. Statistical analyses of HSCT outcome face unique challenges because many clinical endpoints depend on GVT and GVHD, two events that are immunologically intertwined but of diametrically opposite clinical consequences. For this reason, competing risks methodology is an essential part of endpoint estimation in HSCT research. However, the choice of the competing events for an endpoint of interest are far from clear and yet will have significant implications on the estimate itself.  My research objective includes designing and implementing broadly applicable standard definitions of HSCT clinical endpoints and developing guidelines for competing risks data analysis;   promoting the use of competing risks methods in other types of cancer where the importance of competing risks is poorly recognized and thus treatment failure is inappropriately evaluated. 


Matsuoka K, Koreth J, Kim HT, Bascug OG, McDonough SM, Kawano Y, Cutler C, Ho VT, Alyea EP,  Armand P, Antin JH, Soiffer RS, and Ritz J. Restoration of regulatory T cell homeostasis in patients with chronic graft-versus-host disease by interleukin-2 replenishment. Science Translational Medicine. 2013 Apr 3;5(179):179ra43.


Kim HT, Armand P. Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom.  Biol Blood Marrow Transplant. 2013 Jun;19(6):860-6. doi: 10.1016/j.bbmt.2013.01.003. Epub 2013 Jan 7.


Armand PA, Welch S, Kim HT, LaCasce AS, Jacobsen ED, Davids M, MD, Jacobson C, Fisher DC, Brown JR, Coughlin E, Freedman AS, Chen Y. Prognostic Factors for Patients with  Diffuse Large B Cell Lymphoma and  Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era. British Journal of Hematology.  Br J Haematol. 2013 Mar;160(5):608-17.


Rego EM, Kim HT, Ruiz-Argüelles GJ, Uriarte Mdel R, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Chauffaille Mde L, Chiattone C, Martinez L, Meillón LA, Gómez-Almaguer D, Kwaan H, Garcés-Eisele J, Gallagher R, Niemeyer CM, Lowenberg B, Ribeiro R, Lococo F, Sanz MA. Improving the Outcome of Acute Promyelocytic Leukemia Treatment in Developing Countries Through Clinical Networking: Results of the International Consortium on Acute Promyelocytic Leukemia.  Blood. 2013 Jan 14. [Epub ahead of print]. Blood. 2013 Mar 14;121(11):1935-43. 


Nikiforow S, Kim HT, Bindra B,  McDonough S, Glotzbecker B, Armand P, Koreth J, Ho VT,  Alyea EP,   Ritz J, Soiffer RJ, Antin JH, Cutler CS.  A Phase I Study of Alemtuzumab for Steroid-Refractory Chronic Graft-versus-Host Disease.  Biol Blood Marrow Transplant. 2013. In press. Biol Blood Marrow Transplant. 2013 Feb 14. doi:pii: S1083-8791(13)00081-5. 10.1016/j.bbmt.2013.02.009. 


Cutler C, Kim HT,  Bindra B,  Sarantopoulos S, Ho VT, Chen YB,  Rosenblatt J,  McDonough S, Watanaboonyongcharoen P,  Armand P,  Koreth J,  Glotzbecker B,  Alyea EP, Blazar BR, Soiffer RJ,  Ritz J, Antin JH. Rituximab Prophylaxis Prevents Corticosteroid-Requiring Chronic GVHD after Allogeneic Peripheral Blood Stem Cell Transplantation. Blood. 2013. In press.


Cutler C, Multani P, Robbins D, Kim HT, Desponts C, Le T, Lu CC, Yi-Bin Chen YB, Philippe Armand P, Koreth J, Glotzbecker B, Ho VT. Alyea E, Isom M, Kao G, Armant M, Silberstein L, Hoggatt J Thies S, Scadden D, North T, Goessling W, Pelus L, Soiffer RSAntin JH, Ballen K, Ritz J, Mendlein J, Zon L, Shoemaker D. Prostaglandin-Modulated Umbilical Cord Blood Hematopoietic Stem Cell Transplantation. Blood. 2013. In press.


Armand P,  Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, Sorror ML, Lee SJ, H. Deeg J, Storer BE, Applebaum F, Antin JH, Soiffer RJ, Kim HT. A Disease Risk Index (DRI) for Patients Undergoing Allogeneic Stem Cell Transplantation. Blood. 2012 Jul 26;120(4):905-13. doi: 10.1182/blood-2012-03-418202. Epub 2012 Jun 18. PMCID:PMC3412351 


Kim HT, Gray R. Three-Component Cure Rate Model for Non-proportional Alternative in the Design of Randomized Clinical Trials. Clinical Trials: Clin Trials. 2012;9(2):155-63. Epub 2012 Feb 21.


Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J, Soiffer RJ. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011 Dec 1;365(22):2055-66.


Research Departments:


Dana-Farber Cancer Institute
450 Brookline Avenue
CLSB 11020
Boston, MA 02215
Get Directions